There is no content at this time. Please check back later.
CPT code 95165 - What’s a dose for Medicare billing?
Read the full articleMedicare defines a dose, for billing purposes only, as 1cc of extract and does not cover dilutions. Medicare reimbursement is… Allergists commonly bill CPT code 95165, which describes services for the supervision of preparation and provision of antigens for allergen immunotherapy. It is important…

Nominate a FIT for 2024 Annals Award
Read the full articleFITs who publish the best original research or review in Annals will receive a cash award of up to $2,500. Multiple… Have you read outstanding original research or an excellent review in Annals of Allergy, Asthma & Immunology written by a Fellow-in-Training? Consider nominating them…

Get ready for Asthma and Allergy Awareness month 2024
Read the full articleBe prepared for this awareness month, when attention is focused on asthma and allergies. It’s a great opportunity to share… Coming soon – National Asthma and Allergy Awareness Month in May! You’ll want to be prepared for this awareness month, when attention is focused…

2023 MIPS Emergency Exception Applications reopened due to Change Healthcare cyberattack
Read the full articleCMS will only approve applications citing this cyberattack as the basis for requesting reweighting under the MIPS EUC Exception.… In response to the Change Healthcare cyberattack in late February, CMS extended the 2023 MIPS data submission deadline and is now reopening the 2023 MIPS…

Coding Conundrum – E/M plus Testing
Read the full articleRecently we received a query from a member about coding an oral challenge and an office visit on the same… The Advocacy Council often receives queries from members on correctly coding specific scenarios. Recently we received a request about coding an oral challenge and…

Change Healthcare Cyberattack - continuing coverage
Read the full articleHere is the latest update from UnitedHealth Group. We encourage you to bookmark and check the UHG site regularly for… The Advocacy Council is aware many practices have experienced devastating fallout from the Change Healthcare cyberattack – an issue directly affecting cash flow that…

March 2024 Annals highlights
Read the full articleThis month’s articles and reviews provide guidance for these changes in our treatment pathways.… As spring arrives and pollen season begins, the current issue of Annals of Allergy, Asthma and Immunology highlights many of the new changes that are coming to our field. As…

It takes a village
Read the full articleWhat does it take to bring the ACAAI Annual Scientific Meeting to life each year? Believe it or not, planning… One of the most interesting parts of being president of the College is the ability to see many things “up close and personal” that…

AllergyTalk: Two Special Podcasts: Omalizumab for Food Allergy
Read the full articleOn February 16, 2024, the FDA announced the approval of the first biologic medication to treat patients with food allergy,… On February 16, 2024, the FDA announced the approval of the first biologic medication to treat patients with food allergy, omalizumab.…

2024 Cyberattacks cause disruptions
Read the full articleDue to the attack, Change Healthcare's systems are still down, causing struggles for physician practices and hospitals filing claims, as… On Feb. 21, Optum announced that its subsidiary, Change Healthcare, was the victim of a massive cyberattack. Change Healthcare is one of the largest…

Omalizumab for Food Allergy Part 2: Implementation Into Practice
in AllergyTalkRead the full articleIn Part 2, we will discuss important considerations in implementing omalizumab for food allergy in your practice.… On February 16, 2024, the FDA announced the approval of the first biologic medication to treat patients with food allergy, omalizumab! In first part of a two-part…

Omalizumab For Food Allergy – Part 1: Reviewing the Evidence
in AllergyTalkRead the full articleIn first part of a two-part series, we will review the evidence behind the Omalizumab as Monotherapy and as Adjunct… On February 16, 2024, the FDA announced the approval of the first biologic medication to treat patients with food allergy, omalizumab! In first part…

AllergyTalk podcast features OUtMATCH study
Read the full articleThe FDA announced its approval of omalizumab as the first biologic medication to treat patients with food allergy.… As the College previously reported, on Feb. 16, the FDA announced its approval of omalizumab as the first biologic medication to treat patients with food allergy.…

Practice Parameters
Read the full articlePractice Parameters are developed by the Joint Taskforce on Practice Parameters and establish guidelines for diagnosis and management of allergic… Practice Parameters are developed by the Joint Taskforce on Practice Parameters and establish guidelines for diagnosis and management of allergic and immunologic diseases. Practice Parameters…

From the desk of the EMD: The future is here!
Read the full articleArtificial intelligence outperforms pulmonologists in the interpretation of pulmonary function tests. If you did not see this article with the… Artificial intelligence outperforms pulmonologists in the interpretation of pulmonary function tests. If you did not see this article with the title above, then you should…

Coding for E&M visit and allergy testing on the same day
Read the full articleMany third-party payers insist skin tests are a part of an office visit, but this is not the case, and… ACAAI physician members often share questions and issues on DocMatter, the College’s exclusive members-only, private forum for clinical and practice management discussions. A recent…

2024 Call for State Delegates and Regional Super Delegates
Read the full articleThere is still time to be a part of the College’s House of Delegates! We’re looking for State and Super… There is still time to be a part of the College’s House of Delegates (HOD)! The HOD works closely with the College’s national Advocacy…

Addressing Cannabis use with patients
Read the full articleA survey revealed 75% of surveyed allergists were only somewhat knowledgeable about respiratory effects and allergic reactions to cannabis… The College’s new Cannabis Educational Modules educate allergists about cannabis use in patients, the rising concern of cannabis allergy, and ways to effectively discuss cannabis…

Impact of 340B Drug Discount Program
Read the full articleWhile 340B is not the most relevant federal program for allergy practices, it is helpful to have a better understanding… Created in 1992 as section 340B of the Public Health Service Act, the 340B Drug Pricing Program is an important and controversial policy intended…

ERROR!